Kirby McInerney LLP is investigating potential claims against the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (PBTH) related to the proposed acquisition of the Company by OPKO Health, Inc. ("OPKO") (OPK). Under the terms of the proposal, PROLOR shareholders will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. In total, the transaction is valued at approximately $480 million, or $7.00 per share of PROLOR common stock.

The investigation concerns whether the PROLOR Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $7.00 per share consideration adequately values PROLOR common shares.

If you are a PROLOR shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, or by telephone at (212) 699-1145 or (888) 529-4787.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

distributed by